NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
Summary
USD $39.5m).NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. Intesa Sanpaolo Innovation Center has invested in Neva First, the investment fund designed for excellent, high-tech, high-innovation start-ups, which take advantage of trends with exponential growth potential.Chaired by the scientist and entrepreneur Stefano Buono, LIFTTs aim is to encourage technology development and transfer from University to Industry, but also to clear the way from a simple business idea to the creation of an innovative product, offering a dynamic and modern vision of venture capital as applied to Technology Transfer. As a reference point for the Italian fiduciary market, with over 7 billion administered assets, Simon Fiduciaria has developed, alongside fiduciary and trust heading services, an innovative service dedicated to large private and institutional assets, with independent and analytical monitoring that offers an aggregated view of allocation, performance, and risks, and highlights potential areas for improvement.About Sixth Element Capital LLP and the CRT Pioneer FundSixth Element Capital LLP (6EC) is a UK based fund manager, which manages the CRT Pioneer Fund. 6ECs experienced partners focus on creative and collaborative novel financing solutions designed to fund and manage innovative science in order to bring new therapeutic products and technologies to market, creating long term value and benefit to stakeholders. The firms goal is to identify innovative and promising companies that are developing First-in-Class therapeutics for indications with high unmet patient needs and provide them with the financial resources and strategic guidance they need to succeed.